Poseida Therapeutics to Present at Two Upcoming Investor Conferences
Poseida Therapeutics (Nasdaq: PSTX), a clinical-stage company focused on allogeneic cell therapy and genetic medicines, has announced its participation in two major healthcare investor conferences. The company will present at the Stifel 2024 Healthcare Conference on Monday, November 18, 2024, at 10:20am ET, and the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024, at 12:00pm ET.
Webcasts of both presentations will be accessible through Poseida's website and will remain available for approximately 90 days after the events.
Poseida Therapeutics (Nasdaq: PSTX), un'azienda in fase clinica focalizzata sulla terapia cellulare allogenica e sui medicinali genetici, ha annunciato la sua partecipazione a due importanti conferenze per investitori nel settore sanitario. L'azienda presenterà al Stifel 2024 Healthcare Conference lunedì 18 novembre 2024, alle 10:20 ET, e al Piper Sandler 36th Annual Healthcare Conference mercoledì 4 dicembre 2024, alle 12:00 ET.
I webcast di entrambe le presentazioni saranno accessibili tramite il sito web di Poseida e rimarranno disponibili per circa 90 giorni dopo gli eventi.
Poseida Therapeutics (Nasdaq: PSTX), una empresa en fase clínica centrada en la terapia celular alogénica y los medicamentos genéticos, ha anunciado su participación en dos importantes conferencias para inversores en el sector salud. La empresa presentará en la Stifel 2024 Healthcare Conference el lunes 18 de noviembre de 2024, a las 10:20 a.m. ET, y en la Piper Sandler 36th Annual Healthcare Conference el miércoles 4 de diciembre de 2024, a las 12:00 p.m. ET.
Las retransmisiones en vivo de ambas presentaciones serán accesibles a través del sitio web de Poseida y estarán disponibles durante aproximadamente 90 días después de los eventos.
포세이다 치료제(Poseida Therapeutics, Nasdaq: PSTX)는 동종세포 치료 및 유전자 의약품에 중점을 둔 임상 단계 회사로, 두 개의 주요 헬스케어 투자자 회의에 참여할 것을 발표했습니다. 이 회사는 Stifel 2024 Healthcare Conference에서 2024년 11월 18일 월요일 오전 10:20 ET에 발표할 예정이며, Piper Sandler 36th Annual Healthcare Conference에서는 2024년 12월 4일 수요일 오후 12:00 ET에 발표할 예정입니다.
두 발표의 웹캐스트는 포세이다의 웹사이트를 통해 접속할 수 있으며, 행사 후 약 90일 동안 이용 가능합니다.
Poseida Therapeutics (Nasdaq: PSTX), une entreprise en phase clinique spécialisée dans la thérapie cellulaire allogénique et les médicaments génétiques, a annoncé sa participation à deux grandes conférences pour investisseurs dans le secteur de la santé. L’entreprise présentera lors de la Stifel 2024 Healthcare Conference le lundi 18 novembre 2024, à 10h20 ET, et à la Piper Sandler 36th Annual Healthcare Conference le mercredi 4 décembre 2024, à 12h00 ET.
Les webdiffusions des deux présentations seront accessibles via le site Web de Poseida et resteront disponibles pendant environ 90 jours après les événements.
Poseida Therapeutics (Nasdaq: PSTX), ein Unternehmen in der klinischen Phase, das sich auf allogene Zelltherapie und genetische Medizin konzentriert, hat seine Teilnahme an zwei großen Investorenkonferenzen im Gesundheitswesen bekannt gegeben. Das Unternehmen wird am Stifel 2024 Healthcare Conference am Montag, den 18. November 2024, um 10:20 Uhr ET, und am Piper Sandler 36th Annual Healthcare Conference am Mittwoch, den 4. Dezember 2024, um 12:00 Uhr ET präsentieren.
Die Webcasts beider Präsentationen werden über die Website von Poseida zugänglich sein und bleiben etwa 90 Tage nach den Veranstaltungen verfügbar.
- None.
- None.
Stifel 2024 Healthcare Conference
Date: Monday, November 18, 2024
Time: 10:20am ET
Piper Sandler 36th Annual Healthcare Conference
Date: Wednesday, December 4, 2024
Time: 12:00pm ET
Webcasts will be available on the Investors & Media Section of Poseida's website, www.poseida.com. A replay of the webcast will be available for approximately 90 days following the presentation.
About Poseida Therapeutics, Inc.
Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated allogeneic cell therapies and genetic medicines with the capacity to cure. The Company's pipeline includes investigational allogeneic CAR-T cell therapies for hematologic cancers, autoimmune diseases, and solid tumors, as well as investigational in vivo genetic medicines that address patient populations with high unmet medical need. The Company's approach is based on its proprietary genetic editing platforms, including its non-viral transposon-based DNA delivery system, Cas-CLOVER™ Site-Specific Gene Editing System, Booster Molecule and nanoparticle gene delivery technologies, as well as in-house GMP cell therapy manufacturing. The Company has formed strategic collaborations with Roche and Astellas to unlock the promise of cell therapies for cancer patients. Learn more at www.poseida.com and connect with Poseida on X and LinkedIn.
View original content to download multimedia:https://www.prnewswire.com/news-releases/poseida-therapeutics-to-present-at-two-upcoming-investor-conferences-302301700.html
SOURCE Poseida Therapeutics, Inc.
FAQ
When is Poseida Therapeutics (PSTX) presenting at the Stifel Healthcare Conference 2024?
When is Poseida Therapeutics (PSTX) presenting at the Piper Sandler Healthcare Conference 2024?
How long will the webcasts of Poseida Therapeutics (PSTX) conference presentations be available?
Where can I watch Poseida Therapeutics (PSTX) investor conference presentations?
